CA2177367A1 - Proteines et peptides de liaison recombines - Google Patents

Proteines et peptides de liaison recombines

Info

Publication number
CA2177367A1
CA2177367A1 CA002177367A CA2177367A CA2177367A1 CA 2177367 A1 CA2177367 A1 CA 2177367A1 CA 002177367 A CA002177367 A CA 002177367A CA 2177367 A CA2177367 A CA 2177367A CA 2177367 A1 CA2177367 A1 CA 2177367A1
Authority
CA
Canada
Prior art keywords
polypeptide
splicing
intron
sequence
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002177367A
Other languages
English (en)
Inventor
Andrew David Griffiths
Kaspar-Philipp Holliger
Ahuva Nissim
Igor Fisch
Gregory Paul Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1993/002492 external-priority patent/WO1994013804A1/fr
Priority claimed from GB9412147A external-priority patent/GB9412147D0/en
Application filed by Individual filed Critical Individual
Publication of CA2177367A1 publication Critical patent/CA2177367A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
    • C12N2310/1241—Tetrahymena
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Des produits de recombinaison d'ADN comprennent une première séquence exon de nucléotides codant un premier peptide ou polypeptide, une deuxième séquence exon de nucléotides codant un second peptide ou polypeptide, et une troisième séquence de nucléotides placée entre les première et deuxième séquences codant un intron hétérologue, par exemple l'intron de l'ARN préribosomique nucléaire de Tétrahymena thermophila, situé entre les sites d'épissage d'ARN et une séquence de recombinaison spécifique d'un site, tel que loxP, dans l'intron, les exons réunis codant un peptide ou polypeptide obtenu. Ces produits de recombinaison sont utilisés dans des procédés de production de peptides ou polypeptides, la transcription conduisant à l'épissage de l'intron qui permet la traduction d'un peptide ou polypeptide obtenu à chaîne unique. L'invention se rapporte également à des produits de recombinaison d'acide nucléique isolés, constitués principalement d'une séquence de nucléotides codant un intron d'auto-épissage avec une séquence de recombinaison spécifique d'un site dans l'intron, et destinés à créer des produits de recombinaison pour exprimer des peptides ou des polypeptides.
CA002177367A 1993-12-03 1994-12-05 Proteines et peptides de liaison recombines Abandoned CA2177367A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB1993/002492 WO1994013804A1 (fr) 1992-12-04 1993-12-03 Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
WOPCT/GB93/02492 1993-12-03
GB9412147.2 1994-06-17
GB9412147A GB9412147D0 (en) 1993-12-03 1994-06-17 Recombinant binding proteins and peptides

Publications (1)

Publication Number Publication Date
CA2177367A1 true CA2177367A1 (fr) 1995-06-08

Family

ID=10756876

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002177367A Abandoned CA2177367A1 (fr) 1993-12-03 1994-12-05 Proteines et peptides de liaison recombines

Country Status (5)

Country Link
EP (1) EP0731842A1 (fr)
JP (1) JPH09506508A (fr)
AU (1) AU690171B2 (fr)
CA (1) CA2177367A1 (fr)
WO (1) WO1995015388A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030066B2 (en) 2000-12-11 2011-10-04 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US8304189B2 (en) 2003-12-01 2012-11-06 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same

Families Citing this family (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US7102055B1 (en) 1997-11-18 2006-09-05 Pioneer Hi-Bred International, Inc. Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant
NZ504510A (en) 1997-11-18 2002-10-25 Pioneer Hi Bred Int Methods and compositions for increasing efficiency of excision of a viral replicon from T-DNA that is transferred to a plant by agroinfection
PT1034262E (pt) 1997-11-18 2005-10-31 Pioneer Hi Bred Int Composicoes e metodos para a modificacao genetica de plantas
AU745960C (en) 1997-11-18 2003-09-18 Pioneer Hi-Bred International, Inc. A novel method for the integration of foreign DNA into eukaryoticgenomes
PT1086138E (pt) 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
AU3391900A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
KR20020025990A (ko) 1999-08-23 2002-04-04 나가야마 오사무 에이치엠1.24 항원의 발현 증강제
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
WO2003054189A2 (fr) * 2001-12-20 2003-07-03 Sungene Gmbh & Co. Kgaa Procede de conversion de plastides vegetaux
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
WO2004019966A1 (fr) 2002-08-27 2004-03-11 Chugai Seiyaku Kabushiki Kaisha Methode de stabilisation de preparations de solution de proteines
CN100522989C (zh) 2002-09-11 2009-08-05 中外制药株式会社 纯化蛋白质的方法
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1642971B1 (fr) 2003-06-18 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Transporteur du fucose
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
KR101183720B1 (ko) * 2004-01-16 2012-09-17 다우 글로벌 테크놀로지스 엘엘씨 슈도모나스 플루오레센스에서의 포유류 단백질의 발현
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
WO2007055378A1 (fr) 2005-11-14 2007-05-18 Cell Signals Inc. Procede de traitement ou de prevention d’une maladie associee a un trouble fonctionnel des lymphocytes t regulateurs
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (fr) 2005-11-25 2007-05-31 Keio University Agent thérapeutique pour le cancer de la prostate
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP4793360A2 (fr) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Procédés de régulation de la pharmacocinétique sanguine d'anticorps
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
JP5242382B2 (ja) 2006-04-14 2013-07-24 株式会社医学生物学研究所 エフェクター機能を有するポリペプチド変異体
ES2544888T3 (es) 2006-06-08 2015-09-04 Chugai Seiyaku Kabushiki Kaisha Prevención o remedio para enfermedades inflamatorias
WO2008007755A1 (fr) 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha inducteur de mort cellulaire
EP2047862B9 (fr) 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Médicament agissant contre une maladie rénale
RU2009107707A (ru) 2006-08-04 2010-09-10 Новартис АГ (CH) СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
EP2548576B1 (fr) 2006-08-14 2016-11-30 Chugai Seiyaku Kabushiki Kaisha Diagnostic du cancer à l'aide d'anticorps anti-démogléine-3
CA2661023C (fr) 2006-08-18 2017-08-15 Novartis Ag Anticorps specifiques du prlr et leurs utilisations
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
RU2537245C2 (ru) 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
JP5378795B2 (ja) 2006-10-20 2013-12-25 中外製薬株式会社 抗ｈｂ−ｅｇｆ抗体を有効成分として含む医薬組成物
AU2007311946A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
CA2672581A1 (fr) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d'un tel anticorps
US20100111851A1 (en) 2007-01-05 2010-05-06 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
AU2008219972A1 (en) 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
EP2174667B1 (fr) 2007-07-26 2017-01-04 Osaka University Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
WO2009028639A1 (fr) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited Anticorps anti-epha2
EP3127921A1 (fr) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
BRPI0817482B8 (pt) 2007-10-02 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
CN108130327A (zh) 2007-10-11 2018-06-08 第三共株式会社 靶向破骨细胞相关蛋白Siglec-15的抗体
PL2202307T5 (pl) 2007-10-15 2021-10-04 Chugai Seiyaku Kabushiki Kaisha Sposób wytwarzania przeciwciała
EP2230300A4 (fr) 2007-10-24 2012-08-08 Otsuka Chemical Holdings Co Ltd Polypeptide à fonction effectrice améliorée
CN104109208A (zh) 2007-11-14 2014-10-22 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
CN101918452A (zh) 2007-11-15 2010-12-15 中外制药株式会社 与Anexelekto结合的单克隆抗体及其利用
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
CA2708065C (fr) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Agent therapeutique contre le prurit
WO2009075344A1 (fr) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center Agent thérapeutique pour une leucémie mll et une leucémie moz dont la cible moléculaire est le récepteur m-csf, et son utilisation
WO2009085200A2 (fr) 2007-12-21 2009-07-09 Amgen Inc. Anticorps anti-amyloïde et utilisations de ceux-ci
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AU2009203464A1 (en) 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
EP2803675A3 (fr) 2008-01-25 2014-12-24 Amgen, Inc Anticorps anti-ferroportine et procédés d'utilisation
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
WO2009139822A1 (fr) 2008-05-01 2009-11-19 Amgen Inc. Anticorps anti-hepcidine et méthodes d’utilisation associées
WO2009147695A1 (fr) 2008-06-02 2009-12-10 国立大学法人東京大学 Agent anticancéreux
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
KR20110038047A (ko) 2008-06-20 2011-04-13 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 산화 ＬＤＬ／β２ＧＰＩ복합체에 대한 항체 및 그 용도
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
CA2748990A1 (fr) 2008-12-26 2010-07-01 The University Of Tokyo Diagnostic et traitement du cancer a l'aide d'un anticorps anti-lgr7
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
EP2377932B1 (fr) 2009-04-09 2020-11-18 Daiichi Sankyo Company, Limited Anticorps anti-siglec-15
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
EP2270053A1 (fr) 2009-05-11 2011-01-05 U3 Pharma GmbH Anticorps AXL humanisés
EP2436397B1 (fr) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Composition pharmaceutique contenant un antagoniste d'un ligand de la famille de l'egf en tant que composant
SG178190A1 (en) 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
US20120282173A1 (en) 2009-08-17 2012-11-08 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
EP2496604B1 (fr) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Anticorps contre cd20 canine
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US8685524B2 (en) 2010-01-29 2014-04-01 Toray Industries, Inc. Polylactic acid-based resin sheet
NO2535358T3 (fr) 2010-02-10 2018-05-19
EP2543730B1 (fr) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante de région constante d'anticorps
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
PL2616090T3 (pl) 2010-09-17 2023-12-18 Takeda Pharmaceutical Company Limited Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
CA2885176C (fr) 2010-09-22 2018-10-23 Amgen Inc. Immunoglobulines porteuses et leur utilisation
AU2011323784A1 (en) 2010-10-25 2013-05-30 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
SI2634194T1 (sl) 2010-10-29 2018-11-30 Perseus Proteomics Inc. Anti-cdh3 protitelo, ki ima visoko kapaciteto internalizacije
BR112013010574A2 (pt) 2010-10-29 2016-08-09 Daiichi Sankyo Co Ltd anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
US20140038842A1 (en) 2010-12-28 2014-02-06 Xoma Technology Cell surface display using pdz domains
WO2012106615A1 (fr) 2011-02-03 2012-08-09 Xoma Technology Ltd. Procédés et matériaux pour améliorer l'expression d'une protéine fonctionnelle dans des bactéries
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
EP2698431B1 (fr) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Rétention de molécules de liaison à l'antigène dans le plasma sanguin et procédé de modification du caractère immunogène
CN103826657A (zh) 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
EP2700652B1 (fr) 2011-04-18 2018-12-19 The University of Tokyo Diagnostic et traitement du cancer à l'aide d'un anticorps anti-itm2a
EP2703486B1 (fr) 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anticorps anti-b7-h3
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
EP2714735B1 (fr) 2011-06-03 2021-07-21 XOMA Technology Ltd. Anticorps spécifiques du tgf bêta
WO2013002362A1 (fr) 2011-06-30 2013-01-03 中外製薬株式会社 Polypeptide hétérodimérisé
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN107287660A (zh) 2011-09-30 2017-10-24 中外制药株式会社 离子浓度依赖性结合分子文库
KR102366029B1 (ko) 2011-09-30 2022-02-23 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
KR20250078601A (ko) 2011-09-30 2025-06-02 추가이 세이야쿠 가부시키가이샤 항원의 소실을 촉진시키는 항원 결합 분자
EP2765192A4 (fr) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd Molécule se liant à l'antigène pour favoriser la clairance du plasma d'un antigène comprenant un domaine de liaison aux récepteurs de type chaîne saccharidique
EP3603671A3 (fr) 2011-10-28 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Molécule spécifique de cellules souches du cancer
BR112014010257A2 (pt) 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
EP4624490A3 (fr) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Région fc modifiée d'anticorps
CA2865158C (fr) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Molecule de liaison d'antigene destinee a favoriser la disparition d'antigene via le recepteur fc.gamma.riib
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
JPWO2013147212A1 (ja) 2012-03-30 2015-12-14 第一三共株式会社 新規抗Ｓｉｇｌｅｃ−１５抗体
AU2012376421A1 (en) 2012-04-04 2014-11-13 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
AU2013247645B2 (en) 2012-04-09 2019-02-14 Daiichi Sankyo Company, Limited Anti-FGFR2 antibody
IN2014DN07799A (fr) 2012-04-27 2015-05-15 Daiichi Sankyo Co Ltd
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
WO2013180200A1 (fr) 2012-05-30 2013-12-05 中外製薬株式会社 Molécule de liaison d'antigène spécifique à un tissu cible
JPWO2013180201A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
EP4310191A3 (fr) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène contenant une région fc modifiée
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
EA031631B1 (ru) 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (fr) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Conjugué anticorps-médicament produit par liaison par l'intermédiaire d'un lieur ayant une structure hydrophile
DK2918603T3 (en) 2012-11-08 2018-10-15 Univ Miyazaki ANTIBODY STANDING TO SPECIFICALLY RECOGNIZE TRANSFERRIN RECEPTOR
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
CN105358575B (zh) 2013-03-15 2020-09-22 詹森生物科技公司 干扰素α和ω抗体拮抗剂
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
CA2912526C (fr) 2013-05-16 2021-09-14 Kyoto University Procede de determination d'un pronostic de cancer
EP3009518B1 (fr) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Procédé permettant de prédire le pronostic post-thérapie d'un patient atteint de sclérose en plaques à périodes progressives et rémittentes (spppr) et procédé permettant de déterminer l'applicabilité d'une nouvelle thérapie
US20160159919A1 (en) 2013-06-24 2016-06-09 Chugai Seiyaku Kabushiki Kaisha Therapeutic Agent Comprising Humanized Anti-Epiregulin Antibody as Active Ingredient for Non-Small-Cell Lung Carcinoma Excluding Adenocarcinoma
WO2015034052A1 (fr) 2013-09-05 2015-03-12 国立大学法人 宮崎大学 Anticorps qui réagit spécifiquement avec l'intégrine humaine a6b4
TWI673063B (zh) 2013-09-20 2019-10-01 日商中外製藥股份有限公司 抗蛋白ｃ抗體之出血性疾病的治療
CA2925256C (fr) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Procede de production d'un heteromultimere polypeptidique
CA2925897A1 (fr) 2013-09-30 2015-04-02 Daiichi Sankyo Company, Limited Anticorps anti-lps o11
CN105792844B (zh) 2013-10-08 2021-03-02 第一三共株式会社 抗fgfr2抗体和另一药剂的组合
SMT202100473T1 (it) 2013-11-06 2021-09-14 Janssen Biotech Inc Anticorpi anti-ccl17
CA2929044A1 (fr) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Molecule se liant a l'antigene contenant une region variable d'anticorps modifiee
TWI702316B (zh) 2013-12-04 2020-08-21 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
US10654933B2 (en) 2013-12-27 2020-05-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
WO2015099127A1 (fr) 2013-12-27 2015-07-02 中外製薬株式会社 Gène mutant de fgfr gardien et médicament ciblant celui-ci
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
WO2015150900A2 (fr) 2014-03-31 2015-10-08 Debiopharm International Sa Fusions de fgfr
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
EP3185004A4 (fr) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Procédé de mesure de viscosité de solution de protéine
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
JP6788586B2 (ja) 2014-11-19 2020-11-25 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． Ｈｎｌを用いる診断方法
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
EP3095465A1 (fr) 2015-05-19 2016-11-23 U3 Pharma GmbH Combinaison d'un inhibiteur de fgfr4 et d'un chélateur d'acides biliaires
CA2990572C (fr) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Procede pour la preparation selective d'un conjugue anticorps-medicament
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
CN110922481A (zh) 2015-09-24 2020-03-27 第一三共株式会社 抗garp抗体
WO2017082213A1 (fr) 2015-11-09 2017-05-18 国立大学法人京都工芸繊維大学 AGENT DE SÉPARATION POUR DES ANTICORPS POLYCLONAUX HUMAINS DE TYPE IgG DÉRIVÉS DE SÉRUM ET PROCÉDÉ POUR LA SÉPARATION D'ANTICORPS POLYCLONAUX HUMAINS DE TYPE IgG DÉRIVÉS DE SÉRUM L'UTILISANT
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP3378488A4 (fr) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Procédé pour renforcer la réponse immunitaire humorale
KR20180087430A (ko) 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
EP3431102A4 (fr) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha Médicament thérapeutique induisant des lésions cellulaires à utiliser dans le traitement du cancer
WO2018066626A1 (fr) 2016-10-07 2018-04-12 第一三共株式会社 Traitement contre le cancer pharmacorésistant par administration d'un conjugué anticorps anti-her2/médicament
JP7645607B2 (ja) 2016-11-16 2025-03-14 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する方法
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
CN118126180A (zh) 2016-12-22 2024-06-04 第一三共株式会社 抗cd3抗体和包含所述抗体的分子
SG11201906554RA (en) 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
TW201837174A (zh) 2017-02-07 2018-10-16 日商第一三共股份有限公司 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子
EP3604340A4 (fr) 2017-03-24 2021-01-06 Zenyaku Kogyo Co., Ltd ANTICORPS BISPÉCIFIQUE ANTI-IgM/ANTIGÈNE DE SURFACE DE LYMPHOCYTE B
EP3620531A4 (fr) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
US20200115446A1 (en) 2017-06-30 2020-04-16 National University Corporation Hokkaido University Pediatric osteoporosis drug that does not cause growth disorder
CA3071234A1 (fr) 2017-07-27 2019-01-31 Daiichi Sankyo Company, Limited Anticorps anti cd147
EP3444275A1 (fr) 2017-08-16 2019-02-20 Exiris S.r.l. Anticorps monoclonaux anti-fgfr4
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
CA3177215C (fr) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Conjugue anticorps-derive de pyrrolobenzodiazepine
BR112020006860A2 (pt) 2017-10-05 2020-10-20 Daiichi Sankyo Company, Limited composição para depleção de células t citotóxicas
WO2019078344A1 (fr) 2017-10-20 2019-04-25 学校法人兵庫医科大学 Composition médicinale contenant un anticorps du recepteur anti-il -6 pour prévenir l'adhérence post-chirurgicale
MX2020004716A (es) 2017-11-06 2020-11-06 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
CN111836643A (zh) 2018-03-05 2020-10-27 学校法人埼玉医科大学 用于治疗或预防异位骨化的药物组合物
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
JP7549530B2 (ja) 2018-05-21 2024-09-11 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
WO2020016838A2 (fr) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Prédicteurs de réponse prolongée après le traitement avec un anticorps spécifique anti-il23
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
KR20210068079A (ko) 2018-09-28 2021-06-08 추가이 세이야쿠 가부시키가이샤 Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자
CA3119956A1 (fr) 2018-11-14 2020-05-22 Daiichi Sankyo Company, Limited Conjugue anticorps anti-cdh6-derive de pyrrolobenzodiazepine
CN113164594A (zh) 2018-11-20 2021-07-23 株式会社英仙蛋白质科学 向细胞内摄入铁的抑制剂
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
WO2020128864A1 (fr) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
WO2020153467A1 (fr) 2019-01-24 2020-07-30 中外製薬株式会社 Nouveaux antigènes du cancer et anticorps desdits antigènes
EP3932952A4 (fr) 2019-02-28 2022-11-30 Juntendo Educational Foundation Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs
EP3938390A1 (fr) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
MX2021011328A (es) 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
JP7601758B2 (ja) 2019-03-19 2024-12-17 中外製薬株式会社 Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
EP3950061A4 (fr) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited Conjugué anticorps-dérivé de pyrrolobenzodiazépine
BR112021017616A2 (pt) 2019-03-25 2021-11-09 Daiichi Sankyo Co Ltd Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
EP3949988A4 (fr) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited Combinaison d'un conjugué anticorps-dérivé de pyrrolobenzodiazépine et d'un inhibiteur de parp
BR112021020204A2 (pt) 2019-04-10 2021-12-07 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo com região fc modificada
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
EP3972690A4 (fr) 2019-05-23 2023-07-05 Janssen Biotech, Inc. Méthode de traitement de maladie intestinale inflammatoire au moyen d'une polythérapie d'anticorps dirigés contre il -23 et tnf alpha
IL288485B2 (en) 2019-05-29 2026-04-01 Daiichi Sankyo Co Ltd Anti-TROP2 antibody conjugates - a drug for use in cancer treatment
US20200385453A1 (en) 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
CN113905757B (zh) 2019-06-05 2026-01-13 中外制药株式会社 抗体切割位点结合分子
EP4008350A4 (fr) 2019-07-26 2023-06-14 Saitama Medical University Anticorps reconnaissant la région extracellulaire d'alk2/acvr1
US20230220098A1 (en) 2019-09-04 2023-07-13 Perseus Proteomics Inc. Therapeutic drug for polycythemia
CN114630679A (zh) 2019-10-25 2022-06-14 第一三共株式会社 抗garp抗体和免疫调节剂的组合
WO2021107082A1 (fr) 2019-11-27 2021-06-03 株式会社ペルセウスプロテオミクス Agent thérapeutique contre la péritonite carcinomateuse
CN115335082A (zh) 2020-03-27 2022-11-11 光爱科技公司 用于杀死肿瘤细胞的医药品
CA3175577A1 (fr) 2020-03-30 2021-10-07 Mie University Anticorps bispecifique
EP4134099A4 (fr) 2020-04-06 2024-05-29 PhotoQ3 Inc. Médicament pour tuer des cellules tumorales
CA3181949A1 (fr) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Procedes de traitement de la maladie de crohn au moyen d'un anticorps specifique anti-il23
CA3183927A1 (fr) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Methode de traitement d'une maladie intestinale inflammatoire au moyen d'une polytherapie d'anticorps diriges contre il-23 et tnf alpha
EP4174071A4 (fr) 2020-06-24 2024-09-11 The University of Tokyo Colorant photosensibilisant
AU2021308574A1 (en) 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
BR112023000216A2 (pt) 2020-07-28 2023-02-07 Chugai Pharmaceutical Co Ltd Preparação de seringa pré-carregada com agulha, com proteção de agulha e incluindo anticorpo modificado
WO2022024065A1 (fr) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
TW202220677A (zh) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
WO2022045247A1 (fr) 2020-08-27 2022-03-03 学校法人順天堂 Anticorps bispécifique calr-cd3 mutant anti-tronqué et composition pharmaceutique
WO2022075439A1 (fr) 2020-10-08 2022-04-14 国立大学法人東海国立大学機構 Méthode de détermination de sensibilité ou d'effet médicinal d'un anticorps anti-récepteur de la transferrine
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
EP4277665A1 (fr) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Conjugué anticorps-médicament anti-dll3
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
CN117320749A (zh) 2021-03-12 2023-12-29 中外制药株式会社 用于治疗或预防重症肌无力的药物组合物
EP4305062A1 (fr) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Méthode de traitement de patients souffrant de polyarthrite psoriasique ayant une réponse inadéquate à une thérapie par tnf avec un anticorps spécifique anti-il23
TW202304991A (zh) 2021-03-29 2023-02-01 日商第一三共股份有限公司 穩定的多重特異性分子及其利用
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
KR20240049363A (ko) 2021-08-26 2024-04-16 가부시키가이샤 페르세우스 프로테오믹스 Ros(활성 산소종) 생산 증강제
US20240390512A1 (en) 2021-09-15 2024-11-28 Daiichi Sankyo Company, Limited Methods of treating chemotherapy-resistant cancer with an antibody-drug conjugate
US20250000998A1 (en) 2021-09-24 2025-01-02 PhotoQ3 Inc. Medicament for killing tumor cells
EP4412583B1 (fr) 2021-10-04 2026-07-08 Novartis AG Stabilisateurs d'agents tensioactifs
EP4413998A4 (fr) 2021-10-08 2026-02-25 Chugai Pharmaceutical Co Ltd Procédé de préparation d'une formulation de seringue pré-remplie
EP4420683A1 (fr) 2021-10-18 2024-08-28 Daiichi Sankyo Company, Limited Conjugué anticorps anti-cd37-médicament
JP7748680B2 (ja) 2021-11-16 2025-10-03 国立大学法人鳥取大学 改変ｄ領域を含むヒト免疫グロブリン重鎖遺伝子座を有する哺乳動物人工染色体ベクター、及びそのベクターを保持する細胞又は非ヒト動物
WO2023100829A1 (fr) 2021-11-30 2023-06-08 第一三共株式会社 Anticorps musc dégradable par la protéase
KR20240011866A (ko) 2021-12-01 2024-01-26 추가이 세이야쿠 가부시키가이샤 항체 함유 제제의 조제 방법
AU2023218678A1 (en) 2022-02-09 2024-08-01 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
AU2023226293A1 (en) 2022-02-25 2024-09-05 Juntendo Educational Foundation Medicine comprising combination of anti-mutant-calr antibody and another drug
WO2023176881A1 (fr) 2022-03-16 2023-09-21 第一三共株式会社 Combinaison d'une molécule multi-spécifique et d'un inhibiteur de point de contrôle immunitaire
US20250263497A1 (en) 2022-04-19 2025-08-21 Tokai University Educational System Therapeutic agent for nk-cell tumor
KR20250005335A (ko) 2022-04-26 2025-01-09 추가이 세이야쿠 가부시키가이샤 의약 제제 함유 필터 내장 시린지
CN119255825A (zh) 2022-05-24 2025-01-03 第一三共株式会社 抗-cdh6抗体-药物缀合物的剂量方案
CA3266599A1 (fr) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. Anticorps à domaine variable unique spécifiques au fentanyl et utilisation lors d'un essai d'agglutination continue
TW202426486A (zh) 2022-10-25 2024-07-01 日商第一三共股份有限公司 使用針對抑制型ｋｉｒ的促效劑的免疫排斥之迴避方法
CN120548364A (zh) 2023-01-27 2025-08-26 第一三共株式会社 抗lrrc15抗体
KR20250164708A (ko) 2023-03-29 2025-11-25 다이이찌 산쿄 가부시키가이샤 항 cd25 항체 및 항 cd25 항체-약물 콘주게이트
WO2024214811A1 (fr) 2023-04-14 2024-10-17 中外製薬株式会社 Procédé de stabilisation d'une préparation pharmaceutique contenant des protéines
JPWO2024219442A1 (fr) 2023-04-19 2024-10-24
JPWO2025105486A1 (fr) 2023-11-17 2025-05-22
CN122349567A (zh) 2023-12-11 2026-07-07 济世易为生物有限公司 利用反式剪接和拆分型选择标记的蛋白质表达
WO2025198912A1 (fr) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Méthodes de traitement de la myasthénie grave

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59151968A (ja) * 1983-02-21 1984-08-30 テルモ株式会社 カテ−テルの製造方法
WO1992015356A1 (fr) * 1991-03-01 1992-09-17 Baxter International Inc. Catheter cardiovasculaire dote de regions discretes de flexibilite variable
JPH0564660A (ja) * 1991-05-21 1993-03-19 Sumitomo Bakelite Co Ltd 医療用カテーテルおよびその作製方法
PT1024191E (pt) * 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5635381A (en) * 1992-02-26 1997-06-03 Mogen International Nv Agrobacterium bacteria capable of site-specific recombination
JP3231073B2 (ja) * 1992-03-13 2001-11-19 テルモ株式会社 血管カテーテル
EP0656941B1 (fr) * 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Procedes de production d'elements de paires de liaison specifiques

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309520B2 (en) 2000-08-21 2016-04-12 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US8030066B2 (en) 2000-12-11 2011-10-04 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US8945884B2 (en) 2000-12-11 2015-02-03 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiplerecognition sites
US8304189B2 (en) 2003-12-01 2012-11-06 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
US9534252B2 (en) 2003-12-01 2017-01-03 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same

Also Published As

Publication number Publication date
JPH09506508A (ja) 1997-06-30
EP0731842A1 (fr) 1996-09-18
WO1995015388A1 (fr) 1995-06-08
AU690171B2 (en) 1998-04-23
AU1117095A (en) 1995-06-19

Similar Documents

Publication Publication Date Title
AU690171B2 (en) Recombinant binding proteins and peptides
US6010884A (en) Recombinant binding proteins and peptides
JP3507073B2 (ja) 特異的結合対の成員の製造方法
DE69230142T2 (de) Verfahren zur herstellung von spezifischen bindungspaargliedern
AU766253B2 (en) Modulation of polypeptide display on modified filamentous phage
US5427908A (en) Recombinant library screening methods
US7122646B2 (en) Multivalent and multispecific binding proteins, their manufacture and use
CA2035384C (fr) Preparation et utilisation de banques genomiques d'anticorps synthetiques ("bibliotheques d'anticorps synthetiques")
US5922545A (en) In vitro peptide and antibody display libraries
AU762814B2 (en) Selection system
JPH06508511A (ja) 特異的な結合ペアーの構成員の製造方法
US6599697B1 (en) Process for preparing a multicombinatorial library of vectors for expressing antibody genes
JPH11512288A (ja) 結合されたリガンドと受容体ディスプレイ
JP2001509672A (ja) コンビナトリアルライブラリーにおける多様性生成法
JP3994291B6 (ja) 抗体遺伝子発現ベクターのマルチコンビネーションライブラリの作製方法
WO2003097796A2 (fr) Presentation de fabs a la surface d'un bacteriophage t7
Sblattero The Development of a Single Vector Recombination System to Make Large Phage Antibody Libraries

Legal Events

Date Code Title Description
FZDE Discontinued